Below are the three companies in the Biotechnology industry with the highest debt to asset ratios. The Debt/Asset ratio shows the proportion of a company's assets that are financed through debt. If the ratio is greater than one, most of the company's assets are financed through debt.

Anavex Life Sciences ranks highest with a a debt to asset ratio of 13.67. Following is Talon Therapeutics with a a debt to asset ratio of 9.66. Unigene Laboratories ranks third highest with a a debt to asset ratio of 2.84.

MannKind follows with a a debt to asset ratio of 2.44, and NeurogesX rounds out the top five with a a debt to asset ratio of 1.72.

SmarTrend recommended that its subscribers protect gains by selling shares of Anavex Life Sciences on March 20th, 2012 by issuing a Downtrend alert when the shares were trading at $1.33. Since that call, shares of Anavex Life Sciences have fallen 58.5%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time.

http://www.mysmartrend.com/news-briefs/news-watch/highest-debt-asset-ratio-biotechnology-industry-detected-shares-anavex-life--0